Introduction {#S1}
============

Motor impairments of the upper and lower extremities are some of the most common symptoms in patients with MS (Fox et al., [@B6]). Previous investigations have shown muscle weakness, spasticity, and loss of coordination/balance as contributors to these motor decrements (Rizzo et al., [@B22]; Fritz et al., [@B7]; Wagner et al., [@B35]). One area that has been less studied is how alterations in motor patterns generated within the central nervous system (CNS) may play a role. The most common methods for elucidating information about CNS activity during motor task performance are functional magnetic resonance imaging (fMRI) and electroencephalography (EEG). A major limitation of fMRI is that brain activity can only be measured while an individual is positioned within the MR camera (Gramann et al., [@B10]). While EEG is able to measure activity during walking, it can be hampered by interference and is unable to measure subcortical areas (Filippi et al., [@B5]).

An alternative to fMRI and EEG is positron emission tomography (PET). Using the PET glucose analog \[^18^F\]-fluorodeoxyglucose (FDG), the brains utilization/uptake of FDG can be quantified. Glucose is one of the main substrates the brain uses to generate ATP. By measuring FDG uptake into the CNS estimates of brain activity can be made (Ginsberg et al., [@B9]; Niccolini et al., [@B19]). FDG PET also allows for the quantification of all brain regions during any type of free living activity, such as walking, running, or driving a car (Tashiro et al., [@B33]; Jeong et al., [@B12]; La Fougere et al., [@B16]).

Utilizing FDG PET at rest, Roelcke et al. ([@B24]) and Bakshi et al. ([@B3]) found reduced glucose metabolism within the brain of patients with MS compared to healthy controls. Bakshi et al. ([@B3]) also suggested that cerebral dysfunction and neuronal system disconnection, or uncoupling, may play an important role in the symptoms of MS. The purpose of this study was to determine the associations between brain activity, as measured by FDG uptake, and walking ability in patients with MS and healthy controls. We hypothesized that patients with MS would have lower FDG uptake during walking compared to controls, and that associations with brain regions responsible for motor task performance/control are altered in patients with MS.

Materials and Methods {#S2}
=====================

Basic descriptions of the methods utilized in this investigation are provided here. A more detailed explanation can be found in Rudroff et al. ([@B26]). All testing was performed between the hours of 0700 and 1100 to reduce the influence of fatigue on patients with MS.

Participant recruitment {#S2-1}
-----------------------

Eight patients with MS and eight controls participated in this study. Basic inclusion criteria for patients with MS included positive MS diagnosis, ability to walk 15 min without assistance, and no change in disease status/had a relapse within the previous 3 months. Controls were sex matched and without known cardiovascular, neurological, or musculoskeletal disease. All procedures were approved by the Colorado Multi Institutional Review Board and all experiments conformed to the Declaration of Helsinki. Upon arrival to the Colorado Translational Research Imaging Center all participants signed informed consent. Measurements for height, weight, and age were obtained for all participants. Patients with MS were assessed for disability utilizing the patient determined disease steps (PDDS) and the modified Ashworth scale for grading spasticity (MASS). Figure [1](#F1){ref-type="fig"} is a representation of the experimental timeline. Participant characteristics are displayed in Table [1](#T1){ref-type="table"}.

![**Representative image of the experimental timeline**.](fnhum-09-00084-g001){#F1}

###### 

**Subject characteristics and clinical measures**.

  *N*                                                   MS           CON          *P*-value
  ----------------------------------------------------- ------------ ------------ -----------
  Age (years)                                           44.9 (8.6)   37.9 (8.4)   0.122
  Height (cm)                                           175 (8)      176 (7)      0.949
  Weight (kg)                                           78.2 (3.3)   78.2 (6.3)   0.982
  Disease duration (years)                              8.9 (6.2)                 
  PDDS                                                  2 (0-4)                   
  MASS                                                  1 (0-1.5)                 
  Walking speed (m/s)[\*](#tfn3){ref-type="table-fn"}   1.1 (0.2)    1.4 (0.1)    0.014
  RPE                                                   1.7 (1.4)    1.5 (1.1)    0.681

*Age, height, weight, disease duration, walking speed, and RPE are reported as mean (SD)*.

*PDDS, patients determined disease steps; and MASS, modified Ashworth scale for grading spasticity, are reported as median (range)*.

*\*P \< 0.050*.

Walking test {#S2-2}
------------

Participants were asked to walk down a 60 m hallway 3--5 times. The time it took them to walk the middle 20 m was timed with a handheld stopwatch. The two closest times were averaged and this speed was set as the initial speed of the treadmill. After their comfortable walking speed was calculated and set on the treadmill, participants began 15 min of treadmill walking. Any adjustments to this speed were made within the first 2 min. Two minutes after the start of treadmill walking ≈321.9 MBq of FDG was injected into an antecubital vein via a previously inserted catheter. During treadmill walking, participants were asked their rating of perceived exertion (RPE), measured on the 10 point Borg scale, every minute. At the conclusion of treadmill walking, participants were escorted to the PET/computed tomography (CT) camera, and within 2 min underwent the start of PET/CT imaging.

PET/CT imaging {#S2-3}
--------------

Positron emission tomography/CT imaging was performed on a Phillips Hybrid Gemini TF 64 camera (Philips Healthcare, Cleveland, OH, USA). PET images were acquired in list-mode and in 3-D mode, utilizing time-of-flight technology in order to improve the image contrast vs. noise. A standard Colorado Translational Research Imaging Center testing protocol was utilized. PET/CT images were acquired consecutively with the participants' body secured to maintain co-registration of the images.

Image analysis {#S2-4}
--------------

Positron emission tomography images were cropped using Analyze 11.0 (Mayo Clinic, Rochester, MN, USA) to allow for analysis of the brain via the Statistical Parametric Mapping 8 (SPM8)[^1^](#fn1){ref-type="fn"} toolbox for Matlab 2011a (The MathWorks, Inc., Natick, MA, USA). FDG PET images were then transformed into SUV parametric images using voxel by voxel calculation via the formula: SUV = Activity (kBq/cc)/((Injected Activity (MBq)/Body Weight (kg)). After SUV calculation, images were spatially normalized to a tracer specific template into Montreal Neurological Institute (MNI) space, as described in Tuulari et al. ([@B34]). Images were smoothed at 10-mm Full Width at Half Maximum. Smoothed spatially normalized SUV images were then analyzed with SPM8.

A two-sample *t*-test batch process was performed within SPM8 to identify clusters of differing FDG uptake between the two groups (group 1 MS, group 2 CON), utilizing walking speed as a covariate, and a relative threshold masking set at 0.8. *T*-contrasts of "−1 1" and "1 −1" were tested with a *P-value* set to 0.01 and an extent threshold (*k*~e~) = to 0 (voxels). Whole brain and current cluster values were identified at the cluster level. The SUV for regions within the significant cluster level were determined using the automatic anatomic labeling (AAL) template extracted with the marsbar[^2^](#fn2){ref-type="fn"} SPM toolbox. Visual inspection of the overlap between ROIs and SPM threshold output overlaid on the AAL template was performed using MRIcron (Rorden and Brett, [@B25]).

Statistical analysis {#S2-5}
--------------------

Whole brain statistical analysis was performed within SPM8 toolbox and ROI-based Pearson's correlations, brain region to walking speed, were performed with SPSS 22 (IBM Corp, Armonk, NY, USA). Participant characteristics were compared utilizing unpaired *t*-tests. For analysis performed in SPSS, a significant α was set at \<0.050.

Results {#S3}
=======

Subject characteristics {#S3-6}
-----------------------

There were no differences between the MS and CON group for age, height, or weight (*P* \> 0.122). Patients with MS were classified as having mild disability determined from scores of the MASS and PDDS. Patients with MS walked at a slower self-selected speed than controls (*P* = 0.014), but without a difference in RPE (*P* = 0.681). All participant characteristics are provided in Table [1](#T1){ref-type="table"}. These characteristics have been previously reported (Rudroff et al., [@B26]).

SPM analysis {#S3-7}
------------

\[^18^F\]-fluorodeoxyglucose uptake in patients with MS was lower compared to controls, represented by one large cluster (*p*~FWE-corr~ \< 0.001, *q*~FDR-corr~ \< 0.001, *k*~e~ = 93851) (Figure [2](#F2){ref-type="fig"}). This cluster represented \~40% of total brain volume (227456 voxels). No cluster or peak-level regions were found to have higher FDG uptake in patients with MS. Figure [3](#F3){ref-type="fig"} is the cluster-level SPM output for the identified cluster, displaying peak-level information. Table [2](#T2){ref-type="table"} displays SPM output with associated AAL labels defined using MRIcron.

![**Brain regions where patients with MS have lower FDG uptake after walking challenge**. Walking speed has been modeled out as a nuisance factor. Data are thresholded at *P* \< 0.01, FDR corrected.](fnhum-09-00084-g002){#F2}

![**SPM output of the areas of lower FDG uptake in patients with MS compared to controls**. Within cluster information is displayed for the large cluster (*p*~FWE-corr~ \< 0.001, *q*~FDR-corr~ \< 0.001, *k*~e~ = 93851) identified during analysis.](fnhum-09-00084-g003){#F3}

###### 

**SPM analysis of cluster-level differences between patients with MS and healthy controls**.

  *T*    *Z*    *p*~uncorr~   MNI coordinates   Region         
  ------ ------ ------------- ----------------- -------- ----- ----------------------------------------------------
  5.28   3.79   0.000         12                36       −4    Cingulum_Ant_R[^a^](#tfn1){ref-type="table-fn"}
  5.12   3.72   0.000         24                50       −4    Frontal_Sup_Orb_R[^a^](#tfn1){ref-type="table-fn"}
  5.10   3.71   0.000         38                −6       −32   Fusiform_R
  4.84   3.60   0.000         38                22       10    Frontal_Inf_Tri_R
  4.80   3.58   0.000         38                42       40    Frontal_Mid_R
  4.78   3.57   0.000         −28               20       −36   Temporal_Pole_Mid_L
  4.77   3.57   0.000         36                −54      30    Angular_R[^a^](#tfn1){ref-type="table-fn"}
  4.73   3.54   0.000         −24               14       −50   Fusiform_L[^a^](#tfn1){ref-type="table-fn"}
  4.70   3.53   0.000         46                −30      −32   Cerebelum_6\_R[^a^](#tfn1){ref-type="table-fn"}
  4.62   3.49   0.000         34                14       4     Insula_R
  4.62   3.49   0.000         6                 64       −20   Frontal_Sup_Orb_R
  4.60   3.48   0.000         42                −14      −12   Hippocampus_R[^a^](#tfn1){ref-type="table-fn"}
  4.38   3.37   0.000         16                20       −8    Cuadate_R
  4.36   3.36   0.000         −34               −22      −4    Hippocampus_L[^a^](#tfn1){ref-type="table-fn"}
  4.35   3.36   0.000         68                0        6     Temporal_Sup_R[^a^](#tfn1){ref-type="table-fn"}
  4.34   3.35   0.000         −30               −6       −20   Hippocampus_L

*^a^Visually placed in nearest labeled area within the automatic anatomical labeling (AAL) MRIcron template*.

*All locations represent areas of lower activity in the MS group vs. the CON group*.

ROI and walking speed correlations {#S3-8}
----------------------------------

Strong to moderate Pearson correlations were found in 13 out of 15 regions identified from SPM analysis to walking speed within the control group (*r* \> −0.75, *P* \< 0.032). Within the MS group only three regions, the insula (*r* = −0.74, *P* = 0.036), hippocampus (*r* = −0.72, *P* = 0.045), and calcarine sulcus (*r* = −0.77, *P* = 0.026) were found to have statistically significant correlations. In both groups neither the thalamus nor caudate had a significant correlation, although within the control group it was borderline (0.051 ≤ *P* \< 0.063). In general all other areas, while not reaching statistical significance, had a lower Pearson *r*-value compared to the same region within the control group. The uncoupling of FDG uptake and walking speed is visualized for four regions in Figure [4](#F4){ref-type="fig"}. Table [3](#T3){ref-type="table"} lists the all *r*-values and associated *P*-values.

![**Visual representation of correlations between walking speed and brain region FDG uptake**. In each case, the strength of the correlation is less in patients with MS compared to controls. As well as correlations being weaker, patients with MS show no statistical significance while correlations for the control group all reach statistical significance. **(A)** Motor cortex, **(B)** frontal cortex, **(C)** cerebellum, **(D)** anterior cingulate.](fnhum-09-00084-g004){#F4}

###### 

**Pearsons' correlations between walking speed and brain region FDG uptake**.

  Brain region              MS       CON                                              
  ------------------------- -------- --------------------------------------- -------- ---------------------------------------
  Frontal cortex            −0.484   0.224                                   −0.813   0.014[\*](#tfn2){ref-type="table-fn"}
  Occipital cortex          −0.664   0.073                                   −0.786   0.021[\*](#tfn2){ref-type="table-fn"}
  Lateral temporal cortex   −0.664   0.073                                   −0.818   0.013[\*](#tfn2){ref-type="table-fn"}
  Medial temporal cortex    −0.636   0.090                                   −0.832   0.010[\*](#tfn2){ref-type="table-fn"}
  Motor cortex              −0.496   0.241                                   −0.791   0.019[\*](#tfn2){ref-type="table-fn"}
  Cerebellum                −0.424   0.295                                   −0.835   0.010[\*](#tfn2){ref-type="table-fn"}
  Insula                    −0.740   0.036[\*](#tfn2){ref-type="table-fn"}   −0.817   0.013[\*](#tfn2){ref-type="table-fn"}
  Hippocampus               −0.718   0.045[\*](#tfn2){ref-type="table-fn"}   −0.751   0.032[\*](#tfn2){ref-type="table-fn"}
  Anterior cingulum         −0.414   0.308                                   −0.800   0.017[\*](#tfn2){ref-type="table-fn"}
  Precuneus                 −0.603   0.113                                   −0.799   0.017[\*](#tfn2){ref-type="table-fn"}
  Calcarine                 −0.767   0.026[\*](#tfn2){ref-type="table-fn"}   −0.750   0.032[\*](#tfn2){ref-type="table-fn"}
  Lingual                   −0.680   0.064                                   −0.850   0.007[\*](#tfn2){ref-type="table-fn"}
  Fusiform                  −0.626   0.097                                   −0.851   0.007[\*](#tfn2){ref-type="table-fn"}
  Thalamus                  −0.324   0.433                                   −0.680   0.063
  Caudate                   −0.557   0.151                                   −0.704   0.051

*\**P* \< 0.050*.

Discussion {#S4}
==========

Results from SPM analysis showed that patients with MS had lower FDG uptake in \~40% of the brain compared to controls as well as weaker associations with preferred walking speed. Interestingly, the motor cortex, the origin of central motor command, was not found to be associated to walking speed in patients with MS (*r* = −0.496, *P* = 0.241). This data suggest that alterations in task performance in patients with MS, such as walking, may be due to network wide uncoupling of CNS activity.

Lower FDG uptake {#S4-9}
----------------

Roelcke et al. ([@B24]) previously showed a reduced central metabolic rate of glucose in patients with MS. Possible explanations are reduced brain volume and enlarged ventricles (Grassiot et al., [@B11]), which are common effects of MS, and altered glucose metabolism that has been shown in MS and other neurological diseases (Mathur et al., [@B17]). One hypothesis that encompasses both of these factors is that mitochondrial dysfunction can lead to neurodegeneration (Su et al., [@B31], [@B30]; Cambron et al., [@B4]). Amorini et al. ([@B1]) reported greatly elevated serum lactate levels in patients with MS. They suggested this is due to mitochondrial dysfunction, which results in a reduced oxidative capacity, and in turn to a higher lactate concentration. Smith et al. ([@B28]) investigated the effect of infused lactate on resting CNS FDG uptake and found that FDG uptake was reduced with lactate infusion. During exercise, it has also been shown that brain FDG uptake can be reduced. This reduction was correlated with the increase in lactate production (Kemppainen et al., [@B13]), although the intensities at which this was found to happen were 30, 50, and 75% ${\overset{˙}{\text{V}}\text{O}}_{2\max}$. Even though these patients with MS were only mildly disabled, a reduced brain volume and increased lactate utilization could be driving the lower FDG uptake observed in this study.

Reduced associations between brain FDG uptake and walking speed {#S4-10}
---------------------------------------------------------------

Much of our knowledge of brain function has been obtained from lesion studies. In these studies, focal lesions are created or patients with naturally occurring lesions were studied. A hallmark of MS is demyelinated lesions, which can be either active or dormant, throughout the CNS (Kutzelnigg and Lassmann, [@B15]). Often time's clinical disability can be linked to the location and activity of these lesions (Rocca et al., [@B23]; Gil Moreno et al., [@B8]). While no MRI measurements were performed for this study, it is unlikely that any lesions the patients with MS had were all in the same locations.

In the control group, we found moderate to strong correlations with walking speed for most of the brain regions within the identified cluster. Many of these regions are involved in visual--spatial processing, sensory/motor integration, and executive function. It has been reported that the neural network for motor task performance is highly integrative, and not limited to areas like the motor cortex and supplemental motor areas, and can change depending on the task being performed (Neely et al., [@B18]). These areas of cortical activity have also been identified during walking and running in other studies using near infrared spectroscopy (NIRS) (Suzuki et al., [@B32]; Koenraadt et al., [@B14]) as well as during imagined walking with fMRI (Bakker et al., [@B2]). In patients with MS, however, it appears that these network connections are altered, suggesting a decoupling effect of brain activity and motor performance. Only the insular cortex, calcarine sulcus, and hippocampus had a significant association with walking speed in patients with MS. The strength of these correlations was also very similar to those within the healthy control group. Interestingly, the motor cortex in the control group showed a strong correlation to walking speed (*r* = −0.791, *P* = 0.019). The contributions of the motor cortex to steady state walking is not completely understood, with conflicting reports of its activity and importance being stated by multiple sources (Bakker et al., [@B2]; La Fougere et al., [@B16]; Petersen et al., [@B20]; Koenraadt et al., [@B14]). During gait challenges, it has also been shown that areas like the supplemental motor areas and prefrontal areas are more active to account for the continuous alterations necessary to navigate the challenges (Suzuki et al., [@B32]; Bakker et al., [@B2]; Koenraadt et al., [@B14]). With the increase in disability and disease progression, it is possible that these areas are used to a greater extend to maintain ambulation in patients with MS and the inability to fully utilize them during walk may contribute to the slower walking speed observed in these patients.

The calcarine sulcus is located within the primary visual cortex, within the occipital lobe. Visual feedback is important for most motor tasks (Zhang et al., [@B37]; Sarlegna and Mutha, [@B27]). It allows for the proper interpretation of the body in the environment. Visual feedback also plays an important role in the maintenance of balance (Prosperini et al., [@B21]), which is often impaired in patients with MS. The insular cortex is a located medial to the temporal lobe and is known as a motor/sensory association area. The integration of sensory and motor cues are necessary for the continuous updates of motor patterns (Smucny et al., [@B29]), ensuring efficient task performance. The hippocampus connects to the medial temporal lobe. This area has been implicated in motor task performance through fMRI studies of recalled walking (La Fougere et al., [@B16]; Wutte et al., [@B36]). It is believed that this area stores the motor patterns that are recalled during walking. Recall of these motor patterns would mostly occur through connections with the hippocampus as well as sensory/motor connections throughout the cortex of the frontal, parietal, and temporal lobes.

Potential physiological mechanisms for walking impairments in patients with MS {#S4-11}
------------------------------------------------------------------------------

Demyelinating lesions often occur throughout the CNS, with no two individuals having lesions at the exact same loci. The decoupling of the CNS and motor task performance may partially explain why many symptoms, such as difficulties walking, are shared between so many patients with MS. To maintain mental and physical function the brain forms new connections within itself to compensate for damage. This plasticity may result in the network wide alterations in glucose uptake, which we show is uncoupled with motor task performance. It is unclear whether these alterations in glucose uptake are causative of disability, or compensatory to maintain function. Further research is necessary to elucidate how alterations in CNS activity influence motor task performance in patients with MS.

Methodological considerations {#S4-12}
-----------------------------

One limitation of this investigation is the lack of MRI data. Combining structural information like brain volume as well as lesion locations could provide additional insight in to why certain areas were correlated with walking speed while others were not. Brain atrophy is very common in patients with MS. The normalization of their PET image to a standard template could introduce error, which increases with greater atrophy. As the amount of atrophy is increased an SUV image would be stretched more to fit the standard template. If varying amounts of atrophy within the MS existed, it could in part explain the lack of correlation between brain ROI and walking speed. The average disease duration of patients with MS in this study was 8.9 years, with a range of 1--19 years, so varying amounts of atrophy can be expected. However, the three ROIs that were found to be significantly correlated with walking speed in the MS group, has similar *r*-values and *P*-values as that of the control group. Since atrophy is common in MS using individualized MR images for normalization may be able to account for the variance due to atrophy and should be performed in future studies. Another limitation is the lack of a baseline FDG PET image so that relative activation/deactivation could be estimated for the groups. Future studies utilizing both MRI and PET may provide greater information on the associations between structure and function within the human brain. Another aspect to consider is the importance of spinal cord activated motor commands from central pattern generators. It is possible that an increased reliance on these motor neurons could reduce correlations with walking performance and the brain.

Conclusion {#S5}
==========

Mildly disabled patients with MS have been shown to decrements in function task performance. In this sample, these decrements were reflected by a significantly slower self-selected walking speed. These patients also demonstrated reduced FDG uptake into \~40% of the brain. Only 3 out of 15 regions identified within the patients with MS, compared to 13 out of 15 regions in healthy controls, were found to be correlated with their walking speed. This may suggest a decoupling of brain glucose utilization and motor task performance. Whether this decoupling is a compensatory mechanism to maintain function or contributes to the decrements in motor task performance requires further studies. Future research studies need to be conducted to identify how to preserve the associations between brain glucose uptake and motor task performance in order to lessen the effects motor decrements have on the functional abilities of patients with MS.
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